The Equality Act, currently moving through Congress, would make LGBTQ+ discrimination explicitly illegal. Precision Medicine Group believes that this Act is too important to leave its passage to chance. That is why we have joined a group of 446 leading American companies in signing the Business Coalition for the Equality Act. (more…)
Innovators developing gene therapies face a multitude of challenges, from the lab to the FDA. Yet a number of successful strategies are emerging that are mitigating the risks, reducing costs and smoothing out the road to approval. Listen to a panel of gene therapy experts with unique perspectives and real-world experiences share successful approaches in gene therapy development, CDx development and commercialization.
At the Meeting on the Med 2021 Conference, CEO & Co-Founder of Precision Medicine Group Mark Clein gave an informative presentation highlighting Precision ADVANCE, the cell & gene therapy collective™, and how it aligns with our mission to help bring life-changing therapies to those that need them the most.
On-Demand Webinar: Continuing the Conversation-The Future of Reimbursement for Cell and Gene Therapies
Expanding upon his presentation at the recent World EPA Congress, moderator Richard Macaulay and Precision Value & Health have assembled a unique panel of payers from UK, Germany, and Italy, plus experts within Precision to address how innovative reimbursement strategies for cell and gene therapies (C>s) will evolve.
Meeting on the Med 2021 Conference Panel: “Innovation: Shortening the Path to Commercialization in Advanced Therapies”
Clare Sarvary Fourrier, SVP of Operational Strategy (EU) for Precision for Medicine moderates this panel discussion with industry experts to share perspectives on the current state of the cell and gene therapy industry and provide key insights in shortening time-to-market for advanced therapies.
Attending Virtual ISPOR 2021 May 17-20? PRECISIONadvisors and PRECISIONheor will be attending with multiple posters, presentations, and workshops. Three posters and one presentation will have a special focus on Orphan diseases. Stay tuned for valuable insights from our experts that you won’t want to miss!
ASGCT 2021 Conference Panel: Considerations for the Clinical Development of Cell & Gene Therapies Part 2 – Gene Therapy
Directly following the cell therapy panel discussion in part 1, Precision experts Phil Cyr, Deb Phippard and David Parker, and Project Pharma’s Tony Khoury joined C-Suite leaders from advanced therapy companies for “Considerations for the Clinical Development of Cell & Gene Therapies.” Part 2- Gene Therapy.